200 related articles for article (PubMed ID: 9764934)
1. Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.
Beck EJ; Tolley K
Int J STD AIDS; 1998 Sep; 9(9):512-7. PubMed ID: 9764934
[TBL] [Abstract][Full Text] [Related]
2. Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Int J STD AIDS; 1999 Jun; 10(6):357-62. PubMed ID: 10414877
[TBL] [Abstract][Full Text] [Related]
3. Indirect cost of HIV infection in England.
Mullins CD; Whitelaw G; Cooke JL; Beck EJ
Clin Ther; 2000 Nov; 22(11):1333-45. PubMed ID: 11117658
[TBL] [Abstract][Full Text] [Related]
4. What is the cost of getting the price wrong?
Beck EJ; Beecham J; Mandalia S; Griffith R; Walters MD; Boulton M; Miller DL
J Public Health Med; 1999 Sep; 21(3):311-7. PubMed ID: 10528959
[TBL] [Abstract][Full Text] [Related]
5. Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.
Beck EJ; Mandalia S; Griffith R; Beecham J; Walters MD; Boulton M; Miller DL
Pharmacoeconomics; 2000 Jan; 17(1):53-69. PubMed ID: 10747765
[TBL] [Abstract][Full Text] [Related]
6. The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.
Beck EJ; Tolley K; Power A; Mandalia S; Rutter P; Izumi J; Beecham J; Gray A; Barlow D; Easterbrook P; Fisher M; Innes J; Kinghorn G; Mandel B; Pozniak A; Tang A; Tomlinson D; Williams I
Pharmacoeconomics; 1998 Dec; 14(6):639-52. PubMed ID: 10346416
[TBL] [Abstract][Full Text] [Related]
7. Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers.
Sculpher MJ; Gibb D; Ades AE; Ratcliffe J; Duong T
AIDS; 1998 Jul; 12(11):1371-80. PubMed ID: 9708418
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
[TBL] [Abstract][Full Text] [Related]
9. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death.
Currie CJ; Morgan CL; Dixon S; McEwan P; Marchant N; Bearne A; Sharplin P; Peters JR
Diabetes Res Clin Pract; 2004 Sep; 65(3):267-74. PubMed ID: 15331207
[TBL] [Abstract][Full Text] [Related]
10. The association between smoking during pregnancy and hospital inpatient costs in childhood.
Petrou S; Hockley C; Mehta Z; Goldacre M
Soc Sci Med; 2005 Mar; 60(5):1071-85. PubMed ID: 15589675
[TBL] [Abstract][Full Text] [Related]
11. Financial cost of social exclusion: follow up study of antisocial children into adulthood.
Scott S; Knapp M; Henderson J; Maughan B
BMJ; 2001 Jul; 323(7306):191. PubMed ID: 11473907
[TBL] [Abstract][Full Text] [Related]
12. One world, one hope: the cost of providing antiretroviral therapy to all nations.
Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
[TBL] [Abstract][Full Text] [Related]
13. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
[TBL] [Abstract][Full Text] [Related]
15. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
16. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
Anis AH; Hogg RS; Wang XH; Yip B; Palepu A; Montaner JS; O'Shaughnessy MV; Schechter MT
Pharmacoeconomics; 1998 Jun; 13(6):697-705. PubMed ID: 10179705
[TBL] [Abstract][Full Text] [Related]
17. Relationship between TISS and ICU cost.
Dickie H; Vedio A; Dundas R; Treacher DF; Leach RM
Intensive Care Med; 1998 Oct; 24(10):1009-17. PubMed ID: 9840233
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness in the management of patients with oesophageal cancer.
Farndon MA; Wayman J; Clague MB; Griffin SM
Br J Surg; 1998 Oct; 85(10):1394-8. PubMed ID: 9782023
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.
Petrou S; Bischof M; Bennett C; Elbourne D; Field D; McNally H
Pediatrics; 2006 May; 117(5):1640-9. PubMed ID: 16651318
[TBL] [Abstract][Full Text] [Related]
20. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents.
Sculpher M; Thompson E; Brown J; Garry R
BJOG; 2000 Mar; 107(3):340-6. PubMed ID: 10740330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
